Details

Autor(en) / Beteiligte

• Albshesh, Ahmad
• Bannon, Lian
• Sharar Fischler, Tali
• Truyens, Marie
• Vavricka, Stephan R
• Tepes, Katja
• Pugliese, Daniela
• Savarino, Edoardo V
• Zittan, Eran
• Drobne, David
• Roblin, Xavier
• Bar-Gil Shitrit, Ariella
• Armuzzi, Alessandro
• Lobaton, Triana
• Maharshak, Nitsan
• Yanai, Henit
• Ben-Horin, Shomron
• Kopylov, Uri

Titel

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Ist Teil von

• Journal of clinical medicine, 2023-03, Vol.12 (7), p.2503

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn's disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16-22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16-22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, = 0.8 and 48.3% vs. 56%, = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, = 0.8 and 62.5% vs. 70.5%, = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups ( = 0.6). Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line.